Survival and contralateral breast cancer in CHEK2 1100delC breast cancer patients: impact of adjuvant chemotherapy. - Wikidata - wikimedia - TriplyDB

Survival and contralateral breast cancer in CHEK2 1100delC breast cancer patients: impact of adjuvant chemotherapy.

Survival and contralateral breast cancer in CHEK2 1100delC breast cancer patients: impact of adjuvant chemotherapy.

http://www.wikidata.org/entity/Q34113473

about

Contralateral prophylactic mastectomy: current perspectives Contralateral Prophylactic Mastectomy (CPM) Consensus Statement from the American Society of Breast Surgeons: Data on CPM Outcomes and Risks.Current perspectives on CHEK2 mutations in breast cancer.CHEK2 (∗) 1100delC Mutation and Risk of Prostate Cancer.Association between CHEK2 H371Y mutation and response to neoadjuvant chemotherapy in women with breast cancer.Sensitivity to systemic therapy for metastatic breast cancer in CHEK2 1100delC mutation carriers Frequency of Germline Mutations in 25 Cancer Susceptibility Genes in a Sequential Series of Patients With Breast Cancer.Patient survival and tumor characteristics associated with CHEK2:p.I157T - findings from the Breast Cancer Association Consortium Genomic profiling of pelvic genital type leiomyosarcoma in a woman with a germline CHEK2:c.1100delC mutation and a concomitant diagnosis of metastatic invasive ductal breast carcinoma.Contralateral prophylactic mastectomy rate and predictive factors among patients with breast cancer who underwent multigene panel testing for hereditary cancer.

P2860

Q26744320-DEB023FB-BCC1-4090-BFA3-714C55E7CD6C Q31118195-952B9BD2-8717-40F5-973C-07199943AB12 Q33712610-238A3259-5605-4F6E-8F11-5BE1C0ED7A0E Q34560743-DBCF29C9-E651-4F55-9103-9C8619E342D2 Q35228809-1CAE4D21-5849-4989-99EB-661C81AFF43D Q35977371-1194FE61-1B36-4EBC-BD8E-60BDAA64E672 Q36915151-645495C2-20BC-408A-B0B2-1E7BB2B03DBB Q37307937-C75A78FA-0524-47B9-950D-89815E972CD2 Q38780469-3FDEE496-FCBA-4C00-9459-AB12FD98C856 Q55437668-D155BA19-E14A-4A2F-A5F0-7F15C49F42EB

P2860

Survival and contralateral breast cancer in CHEK2 1100delC breast cancer patients: impact of adjuvant chemotherapy.

http://www.wikidata.org/entity/Q34113473

description

2014 nî lūn-bûn

@nan

2014 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Survival and contralateral bre ...... pact of adjuvant chemotherapy.

@ast

Survival and contralateral bre ...... pact of adjuvant chemotherapy.

@en

Survival and contralateral bre ...... pact of adjuvant chemotherapy.

@nl

type

label

Survival and contralateral bre ...... pact of adjuvant chemotherapy.

@ast

Survival and contralateral bre ...... pact of adjuvant chemotherapy.

@en

Survival and contralateral bre ...... pact of adjuvant chemotherapy.

@nl

prefLabel

Survival and contralateral bre ...... pact of adjuvant chemotherapy.

@ast

Survival and contralateral bre ...... pact of adjuvant chemotherapy.

@en

Survival and contralateral bre ...... pact of adjuvant chemotherapy.

@nl

P1433

Q34113473-CDE0F013-A8F8-4681-9725-36A3AA595F8D

P1476

Q34113473-2A5303BE-CFE6-45B1-A4EC-46B1F3DB4861

P2093

Q34113473-15836BAB-12D9-4D28-BEDA-FBDA6787944E

Q34113473-40822138-2177-4CA8-B60B-0873FBA4F324

Q34113473-43DBC5C4-1FA2-466E-B145-47AB24E040C8

Q34113473-461A5DBB-C4BA-4C78-BA29-5EE1B0E7513F

Q34113473-4B131E33-669F-4BF4-84D7-C9B6A64A4B2B

Q34113473-664A2584-9BDB-4733-ABE6-655FEE4BECB0

Q34113473-9237EB00-C3F4-4ABC-9CAE-271069CC562A

Q34113473-FD293F2F-6E48-433A-960A-524FA6747E53

P2860

Q34113473-05F09389-7CA2-4949-8DD5-4B4E97A94FFA

Q34113473-0B4E4F98-0E8B-4FA1-B424-1BE443C3279F

Q34113473-0EAF231D-8F69-4739-8B85-5278030CA802

Q34113473-2234145C-1C68-47CD-B6EA-9DDED774F8C0

Q34113473-2671E6BE-D549-4BFC-8FF8-A8D2DCBCD910

Q34113473-2B0D71AF-D855-4F83-B7CA-655BBA154641

Q34113473-3BD5CE31-E25C-48D5-8343-20B7B5B571A6

Q34113473-3F82F504-83E2-4E6D-B14F-E4EDC9FE1D13

Q34113473-47AD475A-6F39-41A2-84EC-E26909C85BEB

Q34113473-5304B0DE-8C69-414E-AA89-F2E4B71161C8

P2888

Q34113473-07A953E5-BE00-4FB6-BF61-EBAF4AF79B92

P304

Q34113473-EE5F345F-18C2-457A-B06C-608D3CE44278

P31

Q34113473-77E91A29-8AC4-4829-8264-5C0BCDD03203

P356

Q34113473-8AF80BE1-3440-44D6-9961-3A333C63F859

P407

Q34113473-4ED7CDB6-671D-4902-90B9-784DD441ACDE

P433

Q34113473-66EBB3D9-8996-477A-AA24-264094B90E6C

P478

Q34113473-6C3866FD-3A52-4A8A-8EDE-29BA499B1655

P50

Q34113473-20A59730-8C72-4B9B-8039-6F38202EEB29

Q34113473-4C92689E-8924-4AF6-8733-B8E31CE75E41

Q34113473-CDF0ECD1-BDC2-447A-B8C3-9547D7477203

Q34113473-DAEBC11C-9718-4563-8BAF-FDD0C3C5DA15

P577

Q34113473-6BE66BF5-9678-4942-A2B4-D7380B3C55C3

P5875

Q34113473-50F75B5F-BEE2-4DEE-A4D7-F7398885F248

P6179

Q34113473-F958F0B2-6195-470D-8CCF-4EE17167CC82

P698

Q34113473-66099A1E-E435-4074-B6D1-E894667F9225

P921

Q34113473-947BA7CD-E042-4E78-8A53-A4DDB0145EF3

P932

Q34113473-2C410A12-F350-4327-A5A6-87ED23146518

P356

P1433

British Journal of Cancer

P1476

Survival and contralateral bre ...... pact of adjuvant chemotherapy.

@en

P2093

A Jager

http://www.w3.org/2001/XMLSchema#string

A M Sieuwerts

http://www.w3.org/2001/XMLSchema#string

E M Berns

http://www.w3.org/2001/XMLSchema#string

J M Collée

http://www.w3.org/2001/XMLSchema#string

J W M Martens

http://www.w3.org/2001/XMLSchema#string

M E Meijer-van Gelder

http://www.w3.org/2001/XMLSchema#string

M Kriege

http://www.w3.org/2001/XMLSchema#string

P E A Huijts

http://www.w3.org/2001/XMLSchema#string

P2860

Low-penetrance susceptibility to breast cancer due to CHEK2(*)1100delC in noncarriers of BRCA1 or BRCA2 mutations

The CHEK2 gene and inherited breast cancer susceptibility

Adjuvant systemic therapy for breast cancer in BRCA1/BRCA2 mutation carriers in a population-based study of risk of contralateral breast cancer

Risk for contralateral breast cancer among carriers of the CHEK2*1100delC mutation in the WECARE Study.

Survival and prognostic factors in BRCA1-associated breast cancer.

Sensitivity to first-line chemotherapy for metastatic breast cancer in BRCA1 and BRCA2 mutation carriers.

CHEK2*1100delC and susceptibility to breast cancer: a collaborative analysis involving 10,860 breast cancer cases and 9,065 controls from 10 studies.

Correlation of breast cancer susceptibility loci with patient characteristics, metastasis-free survival, and mRNA expression of the nearest genes.

Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers.

Tumour characteristics and prognosis of breast cancer patients carrying the germline CHEK2*1100delC variant

P2888

P304

1004-1013

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/BJC.2014.306

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

111

http://www.w3.org/2001/XMLSchema#string

P50

Antoinette Hollestelle

Caroline Seynaeve

Maartje J. Hooning

P577

2014-06-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

263014266

http://www.w3.org/2001/XMLSchema#string

P6179

1029610259

http://www.w3.org/2001/XMLSchema#string

P698

24918820

http://www.w3.org/2001/XMLSchema#string

P921

P932

4150261

http://www.w3.org/2001/XMLSchema#string